Exvastat Program
Severe Covid-19
Phase 2Active
Key Facts
About Numedicus
Numedicus is a private, UK-based biotech firm specializing in the systematic identification of new uses for existing drugs through its extensive, experimentally validated database. Founded in 2015, the company employs a virtual model, collaborating with partners to advance repurposed candidates through clinical development, as evidenced by its portfolio of licensed programs. Led by industry veteran David Cavalla, Numedicus targets significant unmet medical needs across diverse therapeutic areas, offering a de-risked and capital-efficient approach to drug development.
View full company profileTherapeutic Areas
Other Severe Covid-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| SCN-101 (COVID-19 hIVIG) | Scinai Immunotherapeutics | Phase 2/3 |
| Severe Covid | Genclis | Discovery |
| CSL324 | CSL | Phase 3 |